ALS Clinical Trial Landscape
Data updated: May 20, 2026
343 clinical trials tracked since 2008
ALS is being studied across 343 clinical trials registered since 2008, with 91 programs currently active. The competitive pipeline includes 18 active Phase 3 trials, 54 active Phase 2 trials, and 47 active Phase 1 trials. Top industry sponsors include Eli Lilly, Biogen, Amylyx Pharmaceuticals Inc..
91 active
/
343 total (since 2008)
47
Phase 1 Active
141 total
54
Phase 2 Active
210 total
18
Phase 3 Active
71 total
2
Phase 4 Active
4 total
Top Industry Sponsors
Sorted by active Active Done Failed
Eli Lilly 3 0 0
Biogen 2 4 2
Amylyx Pharmaceuticals Inc. 2 4 0
AB Science 2 1 0
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. 2 0 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT07322003 RECRUITING
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Prilenia n=500
NCT04856982 ACTIVE NOT RECRUITING
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
Biogen n=158
NCT04057898 ACTIVE NOT RECRUITING
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
MediciNova n=234
NCT04302870 RECRUITING
Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial
University of Edinburgh n=1,150
+ 66 more Phase 3 trials — see full database below
ALS — Trials Started by Year (last 10 years)
2016 15
2017 17
2018 19
2019 20
2020 26
2021 33
2022 22
2023 14
2024 24
2025 30
2026 22
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Eli Lilly 3
Biogen 8
Amylyx Pharmaceuticals Inc. 6
AB Science 3
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. 2
Brainstorm-Cell Therapeutics 5
MediciNova 3
Spinogenix 3
Clene Nanomedicine 3
Novartis 2
Active Trials by Phase
Phase 1 47
Phase 2 54
Phase 3 18
Phase 4 2
Enrollment Size Distribution
1-50 182
51-200 102
201-500 36
501-1k 7
1k+ 2
All Industry Sponsors
Sorted by active Active Done Failed
Eli Lilly 3 0 0
Biogen 2 4 2
Amylyx Pharmaceuticals Inc. 2 4 0
AB Science 2 1 0
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. 2 0 0
Brainstorm-Cell Therapeutics 1 4 0
MediciNova 1 2 0
Spinogenix 1 1 1
Clene Nanomedicine 1 1 1
Novartis 1 0 1
Ionis Pharmaceuticals, Inc. 1 1 0
QurAlis Corporation 1 1 0
Insmed Gene Therapy LLC 1 0 0
Vector Y Therapeutics 1 0 0
ProJenX 1 0 0
NCT07322003 RECRUITING
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Prilenia n=500
NCT04856982 ACTIVE NOT RECRUITING
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
Biogen n=158
NCT04057898 ACTIVE NOT RECRUITING
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
MediciNova n=234
NCT04302870 RECRUITING
Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial
University of Edinburgh n=1,150
NCT07325591 NOT YET RECRUITING
Efficacy and Safety of Tazbentetol in ALS Participants
Spinogenix n=430
NCT04768972 ACTIVE NOT RECRUITING
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
Ionis Pharmaceuticals, Inc. n=89
NCT07410806 ENROLLING BY INVITATION
HEALEY ALS Platform Trial - Regimen I NUZ-001
Merit E. Cudkowicz, MD n=160
NCT07321860 NOT YET RECRUITING
This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling
Gipfel Life Sciences GmbH n=60
NCT07174492 NOT YET RECRUITING
Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients
AB Science n=412
NCT06126315 RECRUITING
Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS
Mario Negri Institute for Pharmacological Research n=246
NCT03127267 RECRUITING
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
AB Science n=495
NCT07082192 NOT YET RECRUITING
A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
Shanghai Zhimeng Biopharma, Inc. n=240
NCT06719947 NOT YET RECRUITING
HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial
Universidade Federal do Rio Grande do Norte n=80
NCT06973629 NOT YET RECRUITING
Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)
Brainstorm-Cell Therapeutics n=200
NCT05021536 ACTIVE NOT RECRUITING
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
Amylyx Pharmaceuticals Inc. n=664
NCT06391645 NOT YET RECRUITING
Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis
Beijing Tiantan Hospital n=60
NCT06008249 TERMINATED
Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS)
Stichting TRICALS Foundation n=88
NCT04165824 COMPLETED
Safety Study of Oral Edaravone Administered in Subjects With ALS
Tanabe Pharma America, Inc. n=185
NCT05568615 COMPLETED
Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS
Tanabe Pharma Corporation n=15
NCT04745299 COMPLETED
Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS
Corestemchemon, Inc. n=123
NCT01492686 COMPLETED
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
Tanabe Pharma Corporation n=137
NCT04569084 TERMINATED
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
Tanabe Pharma America, Inc. n=384
NCT04577404 COMPLETED
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Tanabe Pharma America, Inc. n=124
NCT05151471 TERMINATED
Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS
Tanabe Pharma America, Inc. n=202
NCT03293069 COMPLETED
Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis
University Hospital, Lille n=372
NCT05740813 COMPLETED
HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262
Merit E. Cudkowicz, MD n=310
NCT05193994 TERMINATED
Triumeq in Amyotrophic Lateral Sclerosis
Macquarie University, Australia n=419
NCT06658977 TERMINATED
RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial
Macquarie University, Australia n=12
NCT05136885 COMPLETED
HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose
Merit E. Cudkowicz, MD n=161
NCT03548311 COMPLETED
Clinical Trial of Ultra-high Dose Methylcobalamin for ALS
Eisai Co., Ltd. n=130
NCT05178810 COMPLETED
Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis
Ferrer Internacional S.A. n=313
NCT05866926 TERMINATED
Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
Ferrer Internacional S.A. n=201
NCT05619783 COMPLETED
Extension Study Evaluating The Safety And Tolerability of AMX0035
Amylyx Pharmaceuticals Inc. n=352
NCT04944784 TERMINATED
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
Cytokinetics n=489
NCT03280056 COMPLETED
Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients
Brainstorm-Cell Therapeutics n=196
NCT00876772 COMPLETED
Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)
Charite University, Berlin, Germany n=40
NCT02588677 COMPLETED
Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)
AB Science n=394
NCT03836716 TERMINATED
Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial
ZevraDenmark n=120
NCT04615923 COMPLETED
HEALEY ALS Platform Trial - Regimen D Pridopidine
Merit E. Cudkowicz, MD n=163
NCT02623699 COMPLETED
An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)
Biogen n=176
NCT00445172 COMPLETED
A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)
Eisai Co., Ltd. n=135
NCT04436510 COMPLETED
HEALEY ALS Platform Trial - Regimen B Verdiperstat
Merit E. Cudkowicz, MD n=167
NCT04516096 COMPLETED
A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)
Amylyx Pharmaceuticals Inc. n=28
NCT03948178 TERMINATED
Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension
Orion Corporation, Orion Pharma n=227
NCT04248465 TERMINATED
An Efficacy and Safety Study of Ravulizumab in ALS Participants
Alexion Pharmaceuticals, Inc. n=382
NCT03505021 COMPLETED
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
Orion Corporation, Orion Pharma n=496
NCT03068754 TERMINATED
Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)
Mallinckrodt n=143
NCT02496767 COMPLETED
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
Cytokinetics n=744
NCT00868166 COMPLETED
Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS
Hoffmann-La Roche n=512
NCT00965497 COMPLETED
Escitalopram (Lexapro) for Depression MS or ALS
University of South Carolina n=13
NCT00706147 COMPLETED
Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis
University of Miami n=38
NCT01776970 COMPLETED
Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease
Ospedale San Raffaele n=60
NCT01583088 TERMINATED
Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation
Assistance Publique - Hôpitaux de Paris n=74
NCT00839033 TERMINATED
Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders
Assistance Publique - Hôpitaux de Paris n=14
NCT01160263 COMPLETED
Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls
Assistance Publique - Hôpitaux de Paris n=16
NCT01933321 COMPLETED
Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)
Hospital Universitario Dr. Jose E. Gonzalez n=14
NCT01016522 TERMINATED
Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)
Johns Hopkins University n=1
NCT01825551 COMPLETED
The Effect of GCSF in the Treatment of ALS Patients
Tehran University of Medical Sciences n=40
NCT00818389 TERMINATED
Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
Massachusetts General Hospital n=84
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only